-
Recently, a large number of pharmaceutical companies are laying out in the field of large health
Time of Update: 2022-11-25
On the evening of November 7, Puli Pharmaceutical issued an announcement that due to the company's business development needs, in order to realize the company's life-based health business layout, the company intends to use its own funds to invest in the establishment of a wholly-owned subsidiary Zhejiang Puli Health Technology Co.
-
Good news for people with type 1 diabetes! A new FIC drug is launched
Time of Update: 2022-11-25
On November 17, Provention Bio's first-in-class drug Tzield (teplizumab) was approved by the US FDA to delay the disease progression in specific high-risk groups of type 1 diabetes.
-
Retail pharmacies should be vigilant, and the State Food and Drug Administration is cracking down on these practices
Time of Update: 2022-11-25
. On the whole, after the State Food and Drug Administration launched the national drug safety special rectification action, the typical cases exposed in various places since the beginning of this year have the shadow of retail pharmacies, and there are mainly five kinds of violations of laws and regulations: including serious violations of quality management practices for drug sales, sales of counterfeit drugs, sale of expired drugs, sale of inferior drugs, and illegal purchase and sale of drugs.
-
Congratulate! These 20 outstanding women have promoted the development of life sciences
Time of Update: 2022-11-25
Lori Morton, Vice President of Regenomon ResearchLori Morton, Vice President of Regenomon ResearchDr. Lori Morton joined Regeneron as a Junior Scientist and her research work has led to the development of 4 innovative drugs, including REGN, a heart failure therapy that is being tested in Phase 1 clinical trials 5381, along with pozelimab, a monoclonal antibody for rare blood disorders, are currently being tested in Phase 3 clinical trials.
-
Take a glimpse of the true face of KASA from the screenshot of the FDA courseware and think about the grand picture of the future digital review
Time of Update: 2022-11-25
In recent years, the FDA has presented KASA (Knowledge-aided Assessment and Structured) at least once a year at a public meeting Application, Knowledge Assisted Evaluation and Structured Application).
-
This pharmaceutical company continues to innovate, and 2 new drugs have been approved for marketing one after another!
Time of Update: 2022-11-25
With the intensive listing of more innovative drugs, the industry generally believes that Luye Pharmaceutical may be expected to usher in a new round of high-quality development.
-
The pharmaceutical company's executives changed frequently, and 21 people left during the year!
Time of Update: 2022-11-25
On May 31, Unnamed Pharmaceutical announced that the company's board of directors recently received the resignation report submitted by Mr. Li Yan, the company's deputy general manager, and Mr. Li Wei applied to resign as the company's deputy general manager due to personal reasons, and Mr. Li Wei will no longer hold any position in the company after his resignation.
-
Responding to the Challenges of the New 10 Years of Pharmaceutical Changes: Business Differentiation and Product Layout from a Marketing Perspective (Dry Goods)
Time of Update: 2022-11-25
In the past 10 years, medical insurance coverage has continued to increase, payment and demand have greatly expanded, and even homogenized excess capacity can reap relatively large profits. In the pas
-
Is the HER2 ADC track getting tougher? Rongchang, Lepu, Hengrui, and Kelun competed to break through
Time of Update: 2022-11-25
With the defeat of Emmetrituzumab (Kadcyla, T-DM1), HER2 in a head-to-head trial with destristuzumab (DS-8201, T-Dxd). The popularity of the ADC track can be described as reaching a new peak. However,
-
AZ China's first rare disease drug on sale! Under the policy dividend, MNC has increased its layout of rare disease tracks
Time of Update: 2022-11-25
British pharmaceutical giant AstraZeneca announced that its rare disease drug eculizumab (Sulirui) opened its first order in Hangzhou on November 11, 2022, and was officially launched in China. The dr
-
Good news in the eye treatment market! Involving ophthalmic injections, medical products...
Time of Update: 2022-11-25
For example, on November 15, Kanghong Pharmaceutical issued an announcement that KH631 ophthalmic injection declared by its subsidiary Hongji Biotech obtained the drug clinical trial approval notice from the China Medical Products Administration and agreed to carry out clinical trials.
-
Market access and pricing of innovative drugs in Germany
Time of Update: 2022-11-15
Benefit evaluation focuses on "patient-relevant endpoints"Price negotiation phasePrice negotiation phaseAfter G-BA announces the final verdict, the pharmaceutical company will cooperate with GKVde-SV (Gesetzliche Krankenversicherung Spitzenverband, National Federation of Statutory Health Insurance Funds) to G-BA The judgment was based on a six-month four- to five-month negotiation over the reimbursement price of drugs.
-
October biomedical industry operation report: financing increased by more than 40% month-on-month, with 100,000 new enterprises
Time of Update: 2022-11-15
Table 7: New phase III clinical trials were conducted in October Source: Firestone Creation Industry Data Center05 Analysis of drug approval05 In October 2022, a total of 42 products were approved for listing across the country, a decrease of 23.
-
"Fight" family bottom style into the Bo show! Roche AZ Pfizer GSK Sanofi collective "drying muscles", who has the strongest family background? 20 "top goods" spoilers in advance
Time of Update: 2022-11-15
E drug managers continue to pay attention to the 5th year of the Expo, and clearly perceive that at the 2022 Expo, it seems that each MNC has come up with the most competitive innovation "foundation" to show to the entire industry and consolidate confidence in its future development in the Chinese market.
-
Provention Bio shares up 26% as world's first type 1 diabetes drug is about to be approved
Time of Update: 2022-11-15
In the United States, stage 2 There are 200,000 people at risk of potential type 1 diabetes, which is also the applicable population of Teplizumab.
-
AstraZeneca, plus Chinese medicine
Time of Update: 2022-11-15
Industry insiders said that multinational pharmaceutical companies' entry into the field of traditional Chinese medicine is divided into three stages, namely the raw material procurement period, the market wait-and-see period and the in-depth cooperation period.
-
COVID vaccine revenue plunged 66% to $4.4 billion, and Pfizer's third-quarter revenue fell 6%
Time of Update: 2022-11-15
Original link in English: _mstmutation="1" _msthash="220727" _msttexthash="3414710"> The new crown vaccine affected the third quarter results to some extent, but Pfizer still raised the company's full-year revenue guidance.
-
More than 20 investment institutions poured in at the same time, and this track ran low-key
Time of Update: 2022-11-15
The cold air does not seem to blow towards the neuromodulation track. In the context of this year's capital winter, the track is still favored by investment institutions and goes against the trend. It
-
Is the pharmaceutical Q3 report card worthy of this wave of rise?
Time of Update: 2022-11-15
"Cutting back on sales expenses – Slow commercialization – companies can't raise money"In general, the dual difficulties of the epidemic and capital have made the performance of the pharmaceutical industry in the secondary market in the first three quarters of this year unsatisfactory.
-
With more than 200 million yuan and more than 50,000 cases, how will the early screening of pan-cancer species be won?
Time of Update: 2022-11-15
Self-developed multi-omics modelSelf-developed multi-omics modelFrom the information disclosed by the PANDA research project, Nova Health's pan-cancer early screening products have selected a very delicate biomarker, that is, free RNA (cfRNA).
